Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema

Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema

Abstract. Introduction:. Thoracic empyema and concomitant bronchopleural fistula are serious complications of pneumonia. The treatment of empyema caused by extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) has become increasingly challenging. Patient's concerns and important clinical f...

Full description

Bibliographic Details
Main Authors: Tzu-Ting Chen, MS, Shu-Mei Chen, MD, Hsin-Yi Liu, MD
Format: Article
Language:English
Published: Wolters Kluwer 2022-06-01
Series:Medicine
Online Access:http://journals.lww.com/10.1097/MD.0000000000029467

Similar Items

Similar Items